regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
The Analytical Information Markup Language (AnIML) is an open ASTM XML standard for storing and sharing analytical chemistry and biological data. A main reason of using AnIML is that FAIR data (Findable, Accessible, Interoperable and Reusable) standards are automatically implemented. As AnIML's structure is human-readable, Accessibility is given. Interoperability, Reusability and Findability are secured by the AnIML Core and AnIML Technique Definitions. AnIML has been continuously worked on starting from 2003 up to 2020. The last AnIML Core Version update happened in 2010. So far, no standardisation document nor public example files have been published. The standard exists only in pre-release form. AnIML is a XML standard which consists of two logical layers:
In terms of inhibitors of intrinsic termination, much is still unknown. One of the few examples that is known is bacteriophage protein 7. This is made up of 3.4A and 4.0A cryo-EM structures of P7-NusA-TEC and P7-TEC. This bacteriophage protein 7 stops transcription termination by blocking the RNA polymerase (RNAP) RNA-exit channel and impeding RNA-hairpin formation at the intrinsic terminator. Furthermore, bacteriophage protein 7 inhibits RNAP-clamp motions. Shortening the C-terminal half-helix of the RNAP slightly decreases the inhibitory activity. These RNAP clamp motions have been targeted by some other inhibitors of bacterial RNAP. These inhibitors include myxopyronin, corallopyronin, and ripostatin. These work by inhibiting isomerization. RNA polymerases in all three domains of life have some version of factor-independent termination. All of them use poly-uracil tracts, though the exact mechanisms and accessory sequences vary. In archaea and eukaryotes, there appears to be no requirement of a hairpin.
One more very convincing experiment from Dubna was published in 1966 (though it was submitted in 1965), again using the same two reactions, which concluded that 254No indeed had a half-life much longer than the 3 seconds claimed by Berkeley. Later work in 1967 at Berkeley and 1971 at the Oak Ridge National Laboratory fully confirmed the discovery of element 102 and clarified earlier observations. In December 1966, the Berkeley group repeated the Dubna experiments and fully confirmed them, and used this data to finally assign correctly the isotopes they had previously synthesized but could not yet identify at the time. Thus they claimed to have discovered nobelium in 1958 to 1961.
Promising results of health and medical research are reported: non-human vaccinated primates-tested pGal–antigen therapy for suppressing antigen-specific immune responses and against autoimmune diseases, this type of vaccine is called "inverse vaccine" (7 Sep), 3D cell-culture tested exercise-induced hormone irisin against Aβ Alzheimer's disease pathology (8 Sep), identified diverse features strongly associated with long COVID for better diagnosis (25 Sep). Promising innovations relating to global challenges are reported: a study winning an international competition demonstrates an approach that predicted 70% of earthquakes, suggesting some form of earthquake prediction may be feasible in the future (5 Sep), researchers release a large set of audiobooks for books in Project Gutenberg created automatically via generative AI with near-natural voice (7 Sep), a news outlet reports on a natural language system, demonstrated on 27 July, that can provide explanations for the conclusion-making of machine learning models for explainable AI (12 Sep), researchers report a production method for spider silk fibers from gene-edited transgenic silkworms for a sustainable alternative material six times stronger than Kevlar (20 Sep), a new generation of sleeping trains is presented amid a comeback of this transport technology in Europe as demand for more comfortable travel modes than overnight buses and sustainable transport rises (30 Sep).
Sources: en.wikipedia.org
Between 2012 and 2017, the birth rate was 14.3 per thousand and the mortality rate was 10.4 per thousand: even though the Rate of natural increase is positive it does not compensate for the clearly negative net migration rate (-0.7%). In 2017 19% of Le Havre's population was under 15 years old and 39% were under 30 years old, which was above the average for metropolitan France. 24% of men and 26% of women were over 60 years old. The most populous quarters are the city centre, Sanvic, Caucriauville, Anatole France/Danton and Côte Ouest/Ormeaux. In 2009 the foreign population was estimated at 8,525 persons or 4.8% of the population. 12,148 immigrants lived in Havre, or 6.8% of the urban population. Most had North African (5060) or African (3114) origins. With the economic changes that have affected the city, the Professions and Socio-professional categories (PCS) have changed dramatically since the 1980s: between 1982 and 1999, the number of workers has declined by about a third (−10,593), their share of the active labour force was 16% in 1982 and 12.5% in 1999. The population of workers is concentrated in the southern suburbs close to the port and the industrial zone. At the same time the numbers of executives and intellectual professions increased by 24.5%, which is explained in part by the creation and development of the University of Le Havre. In 2017 the city had a lower proportion of managers and intellectual occupations than the national average (14.4% against 18.1%). The proportion of workers (22.5%) was higher than the national average (19.9%).
=== United States === Under the FDA, the process of establishing evidence for vaccine clinical safety and efficacy is the same as for the approval process for prescription drugs. If successful through the stages of clinical development, the vaccine licensing process is followed by a Biologics License Application which must provide a scientific review team (from diverse disciplines, such as physicians, statisticians, microbiologists, chemists) and comprehensive documentation for the vaccine candidate having efficacy and safety throughout its development. Also during this stage, the proposed manufacturing facility is examined by expert reviewers for GMP compliance, and the label must have a compliant description to enable health care providers' definition of vaccine-specific use, including its possible risks, to communicate and deliver the vaccine to the public. After licensure, monitoring of the vaccine and its production, including periodic inspections for GMP compliance, continue as long as the manufacturer retains its license, which may include additional submissions to the FDA of tests for potency, safety, and purity for each vaccine manufacturing step.
Pathology Messaging Implementation Project (PMIP) is the project that introduced universal delivery of electronic pathology results to GPs in Great Britain. The resulting standard was formalised in 2003 as ISB 1557. It uses UN-EDIFACT based messages. More than 20 years later it remains extensively used by the British National Health Service (NHS) to transmit pathology orders and pathology test results. PMIP began in the United Kingdom as the PMEP (Pathology Messaging Enabling Project) under the control of the NHS Information Authority and was supported by the Royal College of Pathologists (Dr Rick Jones), the Royal College of GPs (Dr Stephen Pill) and the British Medical Association. PMIP was designed for the transmission of structured pathology orders and their associated results between pathology and primary care systems. The message definition followed the work on standardisation led by Dr Jonathan Kay and Dr John McVittie and was implemented in UN-EDIFACT as required at the time by the Department of Health. Originally messages were to be encrypted end-to-end (organisation-to-organisation) using public key infrastructure (PKI). The NHS subsequently moved to an alternative strategy using Data Transfer Service (DTS). Messages are encrypted from the pathology laboratory to the DTS server, and again from the DTS server to the General Practitioner using the PMIP interim messaging cryptographic service. The DTS provides application-to-application messaging within the NHS as well as providing a replacement for the X.400 service.
Hezbollah is a Lebanese Shiite political party and paramilitary group, formed in 1982 by Muslim clerics with Iranian funding to fight the Israeli invasion of Lebanon. After the war, Israel continued to hold borderland buffer zone in southern Lebanon with the aid of proxy militants in the South Lebanon Army (SLA). In 2000, Israel withdrew from South Lebanon to the UN-designated and internationally recognized Blue Line border. Hezbollah quickly took control of the area. It has justified its continued existence, occupation, and attacks on Israel by citing both allegations of Lebanese prisoners in Israel and continued Israeli control of the Shebaa farms region, occupied by Israel from Syria in 1967 but considered by Hezbollah to be part of Lebanon. Elimination of the state of Israel has been a primary goal for Hezbollah from its inception. Hezbollah opposes the government and policies of the State of Israel.
Eculizumab (Soliris) appears to be useful for atypical hemolytic uremic syndrome (aHUS). In September 2011 the U.S. Food and Drug Administration (FDA) approved it as an orphan drug to treat people with aHUS. This approval was based on two small prospective trials of 17 people and 20 people. In the UK, NICE issued guidance on the use of Eculizumab for treating aHUS, based on five evidence sources, including those used by the FDA No randomised controlled trials were identified. All prospective studies were phase 2, open‑label, non‑randomised, single‑arm studies that included patients with different clinical baseline characteristics. The prospective studies lasted 26 weeks; however, patients were allowed to continue treatment with eculizumab in a long‑term extension study. Ravulizumab-cwvz (Ultomiris) is a second generation monoclonal antibody for aHUS made by Alexion pharmaceuticals, Inc. The target of ravulizumab-cwvz is the same eculizumab (Soliris) with changes to the structure of the antibody resulting in a longer serum half life and therefore reduced dosing regimen.
Sources: en.wikipedia.org
(See also Nuclear weapon design.) Hypothetically, as little as 4 kg of plutonium—and maybe even less—could be used to make a single atomic bomb using very sophisticated assembly designs. Plutonium-238 is potentially more efficient isotope for nuclear reactors, since it has smaller critical mass than uranium-235, but it continues to release much thermal energy (0.56 W/g) by decay even when the fission chain reaction is stopped by control rods. Its application is limited by its high price (about US$1000/g). This isotope has been used in thermopiles and water distillation systems of some space satellites and stations. The Galileo and Apollo spacecraft (e.g. Apollo 14) had heaters powered by kilogram quantities of plutonium-238 oxide; this heat is also transformed into electricity with thermopiles. The decay of plutonium-238 produces relatively harmless alpha particles and is not accompanied by gamma rays. Therefore, this isotope (~160 mg) is used as the energy source in heart pacemakers where it lasts about 5 times longer than conventional batteries. Actinium-227 is used as a neutron source. Its high specific energy (14.5 W/g) and the possibility of obtaining significant quantities of thermally stable compounds are attractive for use in long-lasting thermoelectric generators for remote use. 228Ac is used as an indicator of radioactivity in chemical research, as it emits high-energy electrons (2.18 MeV) that can be easily detected. 228Ac-228Ra mixtures are widely used as an intense gamma-source in industry and medicine.
=== Stool sugar chromatography === While uncommon today, chromatography can be used to separate and identify undigested sugars present in faeces. Similarly to a stool acidity test, stool sugar chromatography is primarily used to find sugar malabsorption in children due to a lack of other available testing avenues. Although lactose may be detected in the faeces of people with lactose intolerance, this test is not considered reliable enough to conclusively diagnose or exclude lactose intolerance.
(2026) reconstruct the evolutionary history of members of the genus Arvicola in Western Europe during the late Middle and Late Pleistocene on the basis of the study of morphology of teeth from the Lazaret Cave and Moula-Guercy sites (France), Abauntz Cave, Cova Eirós (Spain) and Trou Al'Wesse (Belgium), interpreted as consistent with a complex biogeographic history including multiple dispersals into Western Europe and subsequent local extinctions and recolonizations. New fossil material of members of the genus Byzantinia, providing new information on the morphology of teeth of members of this genus and their evolution, is described from the Miocene strata of the Zahleh Formation (Lebanon) by López-Antoñanzas et al. (2026). A study on the phylogenetic relationships and evolutionary history of extant and extinct hamsters is published by Dirnberger et al. (2026). Bujalska et al. (2026) reconstruct the evolutionary history of European small hamsters on the basis of mitochondrial genomes from Late Pleistocene and Holocene remains from Central and Western Europe, the Balkans and Anatolia, identifying evidence of presence of the winter white dwarf hamster in Central Europe during the Late Pleistocene. Pacheco-Castro, Carranza-Castañeda & Wang (2026) report the discovery of fossil material of Sigmodon minor from the Pliocene strata of the San Miguel de Allende Basin, representing the first record of the species from central Mexico and its southernmost known record in North America.
== Diagnosis == The diagnosis of hypomobility relies on evaluating the patient's history, a physical examination, and quantitative measurement of joint range of motion (ROM) in the affected areas. At this time, there is no universally accepted hypomobility syndrome classification system, and the condition is not formally recognized as a unique diagnostic item in the medical literature. Instead, clinicians describe and document hypomobility based on the degree of motion loss, the number of joints involved, and the underlying causes (when known). During a medical history evaluation, providers record the onset and duration of symptoms. Included in this is any events such as trauma, immobilization, or surgery, and the specific activities affected by stiffness. Patients are usually asked to compare how their motion has changed over time, and to identify and characterize their movements that are now restricted or painful. The physical examination includes comparison of active and passive ROM in the affected joints, using the contralateral limb and age (or sex-matched normative values) as reference points for measurements. According to the American Academy of Orthopaedic Surgeons (AAOS) Clinical Measurement Guidelines, restricted ROM is identified when movement is substantially below normative values. In addition to this, end-feel of motion (firm, capsular, or bony) and the presence of pain at the end of ROM are important diagnostic clues.
== Prevention of plant disease == Control of green mould initially relies on the proper handling of fruit before, during, and after harvesting. Spores can be reduced by removing fallen fruit. Risk of injury can be decreased in a variety of ways, including storing fruit in high humidity and low temperature conditions, and harvesting before irrigation or rainfall in order to minimize fruit susceptibility to peel damage. Degreening practices can also be conducted at humidities above 92% in order to heal injuries. Chemical control in the form of fungicides is also commonly used. Examples include imazalil, thiabendazole, and biphenyl, all of which suppress the reproductive cycle of P. digitatum. Post-harvest chemical treatment usually consists of washes conducted at 40–50 °C (104–122 °F), containing detergents, weak alkalines, and fungicides. California packing houses typically use a fungicide cocktail containing sodium o-phenylphenate, imazalil, and thiabendazole. In Australia, guazatine is commonly used, although this treatment is restricted to the domestic market. In terms of the export market, Generally recognized as safe (GRAS) substances are currently being explored as alternatives. GRAS substances such as sodium bicarbonate, sodium carbonate, and ethanol, have displayed an ability to control P. digitatum by decreasing germination rate. Resistance to common fungicides is currently combated through the use of other chemicals.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.